AlphaYouBH
Insider selling
Benjamin Hohl sold $303K of Enliven Therapeutics, Inc. (ELVN) stock
Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), sold 6,018 shares of ELVN stock worth $303K, per an SEC Form 4 filed Sep 21, 2026.
The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.
The trade happened on Sep 17, 2026, 4 days before it was made public.
ELVN has moved -2.7% since the trade date, from $50.24 to $48.87 (Sep 21, 2026 close).
- Traded
- Sep 17, 2026
- Disclosed
- Sep 21, 2026
- Filing delay
- 4 days
- Price since
- -2.7%
- Role
- Chief Financial Officer
- Source
- SEC Form 4
More ELVN insider and Congress trades
From a public SEC Form 4, linked above. Not investment advice, and not a recommendation to buy or sell.